Merck Announces Second-Quarter 2013 Financial Results

Dateline City: 

WHITEHOUSE STATION, N.J.

2013 Second-Quarter Non-GAAP EPS of $0.84, Excluding Certain Items; GAAP EPS of $0.30
Worldwide Sales were $11.0 Billion, a Decrease of 11 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange Partially Offset by Global Performance of Human Health Products
Growth in Key Franchises Including Vaccines, Diabetes and Immunology
Continued Return of Cash to Shareholders, Including $5 Billion Accelerated Share Repurchase Announced in May
Reaffirmed Full-Year Non-GAAP EPS Target of $3.45 to $3.55, Excluding Certain Items; Revised GAAP EPS Range to $1.84 to $2.05

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced financial results for the second quarter of 2013.

$ in millions, except EPS amounts

SecondQuarter2013

SecondQuarter2012

Language: 

...

Source: Merck.com - Corporate News - July 30, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Latest News Source Type: news